Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug

Clinical Pharmacokinetics

Volumn 36, Issue 4, 1999, Pages 277-287

  Mahmood, Iftekhar ^a,b   Sahajwalla, Chandra ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b Woodmont Office Center II   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ALPRAZOLAM; ANXIOLYTIC AGENT; BUSPIRONE; CIMETIDINE; DILTIAZEM; ERYTHROMYCIN; HALOPERIDOL; ITRACONAZOLE; RIFAMPICIN; SEROTONIN RECEPTOR; VERAPAMIL;

ADULT; AGE; AGED; AREA UNDER THE CURVE; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; DOPAMINERGIC SYSTEM; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; FEMALE; FRUIT JUICE; HUMAN; KIDNEY DISEASE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE;

AGED; ANTI-ANXIETY AGENTS; AREA UNDER CURVE; BUSPIRONE; CLINICAL TRIALS; CROSS-OVER STUDIES; DRUG INTERACTIONS; FEMALE; HUMANS; KIDNEY FAILURE; LIVER CIRRHOSIS; MALE;

EID: 0032904551     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199936040-00003     Document Type: Review

References (48)

1. 1. Riblet LA, Eison SA, Eison MS, et al. Neuropharmacology of buspirone. Psychopharmacology 1984; 17 Suppl. 3: 69-78
2. 2. Temple DL, Yevich JP, New JS. Buspirone: chemical profile of a new class of anxioselective agents. J Clin Psychiatry 1982; 43: 4-9
3. 3. Cimino M, Ponzio F, Achilli G, et al. Dopaminergic effects of buspirone, a novel anxiolytic agent. Biochem Pharmacol 1983; 32: 1069-74
4. 4. Glaser T, Traber J. Buspirone: action on serotonin receptors in calf hippocampus. Eur J Pharmacol 1983; 88: 137-8
5. 2-adrenoceptor blocking properties of buspirone and ipsapirone in healthy subjects: relationship with the plasma concentration of the common metabolite 1-(2-pyrimidinyl)piperazine. Br J Clin Pharmacol 1995; 39: 243-9
6. 1H]flunitrazepam binding in vivo. Eur J Pharmacol 1983; 87: 499-500
7. 7. Kristjansson F. Sensitive determination of buspirone in serum by solid phase extraction and two dimensional high performance liquid chromatography. J Chromatogr 1991; 566: 250-6
8. 8. Tsai TH, Chen CF. Measurement and pharmacokinetic analysis of buspirone by means of brain microdialysis coupled to high performance liquid chromatography with electrochemical detection. J Chromatogr 1997; 762: 269-73
9. 9. Bianchi G, Caccia S. Simultaneous determination of buspirone, gepirone, ipsapirone and their common metabolite 1-(2-pyrimidinyl)piperazine in rat plasma and brain by high performance liquid chromatography. J Chromatogr 1988; 431: 477-80
10. 10. Odontiadis J, Franklin M. Simultaneous quantitation of buspirone and its major metabolite 1-(2-pyrimidinyl)piperazine in human plasma by high performance liquid chromatography with coulometric detection. J Pharm Biomed Anal 1996; 14: 347-51
11. 11. Sciacca MA, Duncan GF, Shea JP, et al. Simultaneous quantitation of buspirone and 1-(2-pyrimidinyl)piperazine in human plasma and urine by capillary gas chromatography mass spectrometry. J Chromatogr 1988; 428: 265-74
12. 12. Gaillard Y, Gay Montchamp JP, Ollagnier M. Simultaneous screening and quantitation of alpidem, zolpidem, buspirone and benzodiazepines by dual channel gas chromatography using electron capture and nitrogen phosphorus detection after solid phase extraction. J Chromatogr 1993; 622: 97-208
13. 13. Betto P, Meneguz A, Ricciarello G, et al. Simultaneous high performance liquid chromatographic analysis of buspirone and its metabolite 1-(2 pyrimidinyl)-piperazine in plasma using electrochemical detection. J Chromatogr 1992; 575: 17-21
14. 14. Kerns EH, Bullen WW, Gammans RE. Quantitative analysis of 1-(2-pyrimidinyl)piperazine in plasma by capillary gas chromatography mass spectrometry. J Chromatogr 1986; 377: 195-203
15. 15. Gammans RE, Kerns EH, Bullen WW. Capillary gas chromatographic mass spectrometric determination of buspirone in plasma. J Chromatogr 1985; 345: 285-97
16. 16. Goldthwaite Jr CA, Hsieh FY, Womble SW, et al. Liquid chromatography/chemical reaction interface mass spectrometry as an alternative to radioisotopes for quantitative drug metabolism studies. Anal Chem 1996; 68: 2996-3001
17. 14C-buspirone HCl after intravenous and oral dosing in man [abstract]. Clin Pharmacol Ther 1985; 37: 210
18. 18. Jajoo HK, Mayol RF, LaBudde JA, et al. Metabolism of the antianxiety drug buspirone in human subjects. Drug Metab Disp 1989; 17: 634-40
19. 19. Gammans RE, Mayol RF, Eison ME. Concentration of buspirone and 1-pyrimidinylpiperazine, a metabolite in rat brain [abstract]. Fed Proc 1983; 42: 377
20. 20. Bullen WW, Bivens DL, Gammans RE, et al. The binding of buspirone to human plasma proteins [abstract]. Fed Proc 1985; 44: 1123
21. 21. Gammans RE, Mayol RF, Mackenthun AV, et al. The relationship between buspirone bioavailability and dose in healthy subjects. Biopharm Drug Disp 1985; 6: 139-45
22. 22. Barbhaiya RH, Shukla UA, Pfeffer M, et al. Disposition kinetics of buspirone in patients with renal or hepatic impairment atter administration of single and multiple doses. Eur J Clin Pharmacol 1994; 46: 41-7
23. 23. Mayol RF, Gammans RE, Mackenthun AV, Sokya LF. The effect of food on the bioavailability of buspirone HCl [abstract]. Clin Res 1983; 31: 631A
24. 24. Caccia S, Vigano GL, Mingardi G, et al. Clinical pharmacokinetics of oral buspirone in patients with impaired renal function. Clin Pharmacokinet 1988; 14: 171-7
25. 25. Dalhoff K, Poulsen HE, Garred P, et al. Buspirone pharmacokinetics in patients with cirrhosis. Br J Clin Pharmacol 1987; 24: 547-50
26. 26. Gammans RE, Mayol RF, LaBudde JA. Metabolism and disposition of buspirone. Am J Med 1986; 80 Suppl. 3B: 41-51
27. 27. Lamberg TS, Kivisto KT, Neuvonen PJ. Effects of verapamil and diltiazem on the pharmacokinetics and pharmacodynamics of buspirone. Clin Pharmacol Ther 1998; 63: 640-5
28. 28. Kivisto KT, Lamberg TS, Kantola T, et al. Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole. Clin Pharmacol Ther 1997; 62: 348-54
29. 29. Erwin CW, Linnoila M, Hartwell J, et al. Effects of buspirone and diazepam, alone and in combination with alcohol, on skilled performance and evoked potentials. J Clin Psychopharmacol 1986; 6: 199-209
30. 30. Ashton CH, Rawlins MD, Tyrer SP. A double blind placebo controlled study of buspirone in diazepam withdrawal in chronic benzodiazepine users. Br J Psychiatry 1990; 157: 232-8
31. 31. van Laar MW, Volkerts ER, van Willigenburg AP. Therapeutic effects and effects on actual driving performance of chronically administered buspirone and diazepam in anxious outpatients. J Clin Psychopharmacol 1992; 12: 86-95
32. 32. Gammans RE, Pfeffer M, Westrick ML, et al. Lack of interaction between cimetidine and buspirone. Pharmacotherapy 1987; 7: 72-9
33. 33. Ciraulo DA, Barnhill JG, Ciraulo AM, et al. Alterations in pharmacodynamics of anxiolytics in abstinent alcoholic men: subjective responses, abuse liability, and electroencephalographic effects of alprazolam, diazepam, and buspirone. J Clin Pharmacol 1997; 37: 64-73
34. 34. Lamberg TS, Kivisto KT, Neuvonen PJ. Concentrations and effects of buspirone are considerably reduced by rifampicin. Br J Clin Pharmacol 1998; 45: 381-5
35. 35. Buch AB, Van Harken DR, Seidehamel RJ, et al. A study of pharmacokinetic interaction between buspirone and alprazolam at steady state. J Clin Pharmacol 1993; 33: 1104-9
36. 36. Huang HF, Jann MW, Wei FC, et al. Lack of pharmacokinetic interaction between buspirone and haloperidol in patients with schizophrenia. J Clin Pharmacol 1996; 36: 963-9
37. 37. Olkkhola VA, Neuvonen PJ. Diltiazem enhances the effects of triazolam by inhibiting its metabolism. Clin Pharmacol Ther 1996; 59: 369-75
38. 38. Backman JT, Olkkola KT, Aranko K, et al. Dose of midazolam should be reduced during diltiazem and verapamil treatments. Br J Clin Pharmacol 1994; 37: 221-5
39. 39. Schlanz KD, Myre SA, Bottorff MB. Pharmacokinetic interactions with calcium channel antagonists: Part I. Clin Pharmacokinet 1991; 21: 344-56
40. 40. Schlanz KD, Myre SA, Bottorff MB. Pharmacokinetic interactions with calcium channel antagonists: Part II. Clin Pharmacokinet 1991; 21: 448-60
41. 41. Lilja JJ, Kivisto KT, Backman JT, et al. Grapefruit juice substantially increases plasma concentrations of buspirone. Clin Pharmacol Ther 1998; 64: 655-60
42. 42. Kolars JC, Schmiedline-Ren P, Schuetz JD, et al. Identification of rifampicin-induced P450IIIA (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992; 90: 1871-8
43. 43. Dawson GW, Jue SG, Brogden RN. Alprazolam: a review of its pharmacodynamic properties and efficacy in the treatment of anxiety and depression. Drugs 1984; 11: 132-47
44. 44. Sethy VH, Harris DW. Determination of biological activity of alprazolam, triazolam and their metabolites. J Pharm Pharmacol 1982; 34: 115-6
45. 45. Desmond PV, Patwardhan RW, Schenkar S, et al. Cimetidine impairs elimination of chlordiazepoxide in man. Ann Intern Med 1980; 93: 266-8
46. 46. Klotz U, Reimann I. Delayed clearance of diazepam due to cimetidine. N Engl J Med 1980; 302: 1012-4
47. 47. Goff DC, Midha KK, Brotman AW, et al. An open trial of buspirone added to neuroleptics in schizophrenic patients. J Clin Psychopharmacol 1991; 11: 193-7
48. 48. Kivisto KT, Lamberg TS, Neuvonen PJ. Interactions of buspirone with itraconazole and rifampicin: effects on the pharmacokinetics of the active 1-(2-pyrimidinyl)-piperazine metabolite of buspirone. Pharmacol Toxicol 1999; 84: 94-7